Biomerica, Inc. (BMRA) DCF Valuation

Biomerica, Inc. (BMRA) DCF Valuation

US | Healthcare | Medical - Devices | NASDAQ
Biomerica, Inc. (BMRA) DCF Valuation
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Biomerica, Inc. (BMRA) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Save time and improve accuracy with our (BMRA) DCF Calculator! Utilizing real Biomerica data and customizable assumptions, this tool allows you to forecast, analyze, and value Biomerica, Inc. like a seasoned investor.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020
AY2
2021
AY3
2022
AY4
2023
AY5
2024
FY1
2025
FY2
2026
FY3
2027
FY4
2028
FY5
2029
Revenue 6.7 7.2 18.9 5.3 5.4 5.9 6.5 7.1 7.7 8.5
Revenue Growth, % 0 7.57 162.14 -71.71 1.42 9.32 9.32 9.32 9.32 9.32
EBITDA -2.3 -7.1 -3.9 -6.7 -6.0 -4.2 -4.6 -5.0 -5.5 -6.0
EBITDA, % -33.97 -98.03 -20.87 -126.2 -110.67 -70.58 -70.58 -70.58 -70.58 -70.58
Depreciation .4 .4 .6 .4 .4 .3 .4 .4 .4 .5
Depreciation, % 5.96 5.22 3.15 6.57 6.91 5.56 5.56 5.56 5.56 5.56
EBIT -2.7 -7.4 -4.5 -7.1 -6.4 -4.3 -4.7 -5.1 -5.6 -6.2
EBIT, % -39.93 -103.25 -24.02 -132.78 -117.58 -72.79 -72.79 -72.79 -72.79 -72.79
Total Cash 8.6 4.2 5.9 9.7 4.2 4.3 4.7 5.2 5.7 6.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 1.8 1.5 .8 .7 .9
Account Receivables, % 26.38 20.21 4.1 13.52 17.49
Inventories 2.9 3.2 2.4 2.1 2.4 2.2 2.4 2.6 2.8 3.1
Inventories, % 42.6 44.53 12.8 38.51 43.88 36.46 36.46 36.46 36.46 36.46
Accounts Payable .8 .4 .7 .3 .3 .4 .4 .5 .5 .6
Accounts Payable, % 12.45 5.99 3.9 6.44 5.32 6.82 6.82 6.82 6.82 6.82
Capital Expenditure -.1 -.3 -.2 -.1 -.1 -.1 -.1 -.1 -.2 -.2
Capital Expenditure, % -1.78 -4.11 -0.90261 -1.46 -2.12 -2.07 -2.07 -2.07 -2.07 -2.07
Tax Rate, % -0.70755 -0.70755 -0.70755 -0.70755 -0.70755 -0.70755 -0.70755 -0.70755 -0.70755 -0.70755
EBITAT -2.7 -7.4 -4.6 -7.1 -6.4 -4.3 -4.7 -5.1 -5.6 -6.2
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -6.2 -7.8 -2.4 -6.8 -6.8 -3.8 -4.7 -5.2 -5.7 -6.2
WACC, % 5.27 5.27 5.27 5.27 5.27 5.27 5.27 5.27 5.27 5.27
PV UFCF
SUM PV UFCF -21.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -6
Terminal Value -193
Present Terminal Value -149
Enterprise Value -171
Net Debt -3
Equity Value -168
Diluted Shares Outstanding, MM 17
Equity Value Per Share -9.96

What You Will Get

  • Genuine Biomerica Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Biomerica, Inc. (BMRA).
  • Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates to suit your analysis.
  • Immediate Valuation Adjustments: Automatic recalculations to assess the effects of changes on Biomerica’s fair value.
  • Flexible Excel Template: Designed for quick modifications, scenario testing, and thorough projections.
  • Efficient and Precise: Avoid starting from scratch while ensuring accuracy and adaptability in your financial models.

Key Features

  • Comprehensive DCF Model: Features detailed unlevered and levered DCF valuation frameworks tailored for Biomerica, Inc. (BMRA).
  • WACC Analysis Tool: Ready-to-use Weighted Average Cost of Capital calculator with adjustable parameters.
  • Customizable Forecast Inputs: Easily alter growth projections, capital investments, and discount rates.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency metrics specific to Biomerica, Inc. (BMRA).
  • Interactive Dashboard and Visuals: Graphical representations highlight essential valuation indicators for straightforward interpretation.

How It Works

  • 1. Access the Template: Download and open the Excel file featuring Biomerica, Inc.'s preloaded data.
  • 2. Modify Assumptions: Adjust key inputs such as growth rates, WACC, and capital expenditures.
  • 3. Analyze Results Instantly: The DCF model automatically computes intrinsic value and NPV.
  • 4. Explore Scenarios: Evaluate various forecasts to assess different valuation outcomes.
  • 5. Present with Assurance: Share professional valuation insights to bolster your decision-making.

Why Choose This Calculator for Biomerica, Inc. (BMRA)?

  • Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses tailored for Biomerica, Inc. (BMRA).
  • Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios.
  • Detailed Insights: Automatically computes Biomerica’s intrinsic value and Net Present Value.
  • Preloaded Data: Historical and projected data provide reliable foundations for analysis.
  • Professional Quality: Perfect for financial analysts, investors, and business consultants focusing on Biomerica, Inc. (BMRA).

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling Biomerica, Inc. (BMRA) stock.
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Biomerica, Inc. (BMRA).
  • Consultants: Deliver professional valuation insights regarding Biomerica, Inc. (BMRA) to clients quickly and accurately.
  • Business Owners: Understand how companies like Biomerica, Inc. (BMRA) are valued to guide your own strategic decisions.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to Biomerica, Inc. (BMRA).

What the Template Contains

  • Preloaded BMRA Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.